Uk's medicines and healthcare products regulatory agency (mhra) supports expedited review of marketing authorization application for sabizabulin treatment in hospitalized covid-19 patients

Miami, july 25, 2022 (globe newswire) -- veru inc. (nasdaq: veru), a biopharmaceutical company focused on developing novel medicines for covid-19 and other viral and ards-related diseases and for the management of breast and prostate cancers, today announced that the united kingdom's (uk's) medicines and healthcare products regulatory agency (mhra) considers that the currently available safety and efficacy data will support an expedited review of the marketing authorization application for the company's sabizabulin treatment in hospitalized covid-19 patients at high risk for acute respiratory distress syndrome (ards) when the application is submitted.
VERU Ratings Summary
VERU Quant Ranking